Profound response to venetoclax monotherapy in a patient with BCL-2 positive relapsed multiple myeloma and extramedullary CNS manifestations

Leuk Lymphoma. 2022 Nov;63(11):2706-2710. doi: 10.1080/10428194.2022.2095625. Epub 2022 Jul 6.

Authors

David M Cordas Dos Santos^{1

2

3}, Tanja Paul⁴, Wolfgang G Kunz⁵, Martina Rudelius⁴, Sebastian Theurich^{1

2

3}

Affiliations

¹ Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
² Cancer- and Immunometabolism Research Group, Gene Center LMU, Munich, Germany.
³ German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁴ Institute of Pathology, LMU Munich, Munich, Germany.
⁵ Department of Radiology, University Hospital, LMU Munich, Germany.

PMID: 35793435
DOI: 10.1080/10428194.2022.2095625

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Bridged Bicyclo Compounds, Heterocyclic / adverse effects
Humans
Multiple Myeloma* / diagnosis
Multiple Myeloma* / drug therapy
Proto-Oncogene Proteins c-bcl-2 / genetics
Sulfonamides / therapeutic use

Substances

venetoclax
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
Proto-Oncogene Proteins c-bcl-2